In p53-null orthotopic and ectopic models of murine HCC, the CTCE-decorated nanocarriers combined with anti-PD-1 therapy enabled global reprogramming of the immune TME, leading to improved tumor inhibition effects compared to individual therapy alone. This evidence concerns the gene TP53 and neoplasm.